ReviewCancers2025
Diffuse Large B-Cell Lymphoma in the Older and Frail Patient.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Chemotherapy-Free Polatuzumab Vedotin and Rituximab (Pola-R) for Frail, Older Patients with Relapsed DLBCL: A Case for Geriatric Assessment and Shared Decision-Making.Reports (MDPI) · 2026Article
- A novel prognostic model integrating host vulnerability and tumor biology for elderly patients with diffuse large B-cell lymphoma: the BAMAL score.Frontiers in oncology · 2026Article
- Efficacy, toxicity, and prognostic factors of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in elderly patients with diffuse large B-cell lymphoma: a single-center retrospective cohort study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outcomes in older, unfit, and frail patients with diffuse large B-cell lymphoma (DLBCL) are inferior compared to younger and fit patients. Despite tremendous progress in the treatment landscape of DLBCL, few clinical trials have focused specifically on this high-risk patient population. This review focuses on the pathophysiology unique to the older patient with DLBCL, as well as the evidence behind current treatment approaches. This article also aims to highlight emerging prognostic tools and novel treatment strategies that may improve the outcomes in this patient cohort in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.